TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Illumina Inc (ILMN)

Healthcare Diagnostics & Research
205.10 $
+0.0% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Illumina Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 15 of our scanner strategies — each hit links to the scanner.

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Trading Day

Previous Close
205.10$
Open
203.30$
Day High
205.90$
Day Low
192.70$
Volume
4,098,585shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
91.00 $ 205.10 $
10/14/2025 07/31/2026

Current price 205.10 $ — 100% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
31.0$B
Shares Outstanding
151Mio.
Float
97.6%
Beta
1.5

Performance

Perf. 1M
14.10%
Perf. 3M
53.90%
Perf. 6M
33.80%
YTD Performance (%)
25.70%
52-Week-High Distance
-2.8%
Perf. 1Y
99.69%
Perf. 3Y
9.73%
Perf. 5Y
-57.47%
Perf. 10Y
26.75%
Perf. Since Inception
976.50%

Technical Indicators

MA 38 Days
181.40$
MA 50 Days
175.40$
MA 200 Days
139.70$
RSI (14)
67.5
Volatility 30 Days
38.8%
Volatility 250 Days
45.8%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
37.0
Forward P/E
39.1
PEG
3.6
P/B
11.6
P/S
6.9
EV/EBITDA
29.3
Price/FCF
33.0

Profitability

Gross Margin
67.9%
EBIT Margin
18.3%
Net Margin
18.3%
Return on Equity
33.8%
Return on Assets
8.7%

Balance Sheet & Safety

Equity Ratio
40.8%
Debt/Equity
1.8
fortress balance sheet
Altman Z″
6.18
Piotroski
5 out of 9

Growth

Sales Growth Last Quarter
4.80%
EPS Growth Last Quarter
6.10%
Sales Growth (Year)
-0.78%
Forward Sales Growth
5.71%
Forward EPS Growth
13.40%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
2
RS Rating
83
EPS Rating
55
Piotroski
5 out of 9
Fundamental Rating
B (55 out of 100)
fortress balance sheet
Altman Z″
6.18

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 205.10 $
Price Target (average) 193.05 $

The price target sits 5.9% below the current price.

Consensus
Sell
Analyst Ratings
20
Distribution of Recommendations
Strong Buy 8
Buy 3
Hold 6
Sell 2
Strong Sell 1

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 5.33 5.25 – 5.40 4,615 10.2% 19
12/31/2027 6.05 5.61 – 6.56 4,891 13.5% 20

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 1,104.0 $M Q4 2025: Q1 · 1,041.0 $M Q1 2025: Q2 · 1,057.0 $M Q2 2025: Q3 · 1,083.0 $M Q3 2025: Q4 · 1,160.0 $M Q4 2026: Q1 · 1,091.0 $M Q1 2026: Q2 · 1,159.0 $M Q2

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 1.17 1,104 -1.60 16.90 364 335
2025: Q1 0.82 1,041 -3.30 12.60 240 201
2025: Q2 1.50 1,057 -4.90 22.20 234 211
2025: Q3 0.97 -77.90 1,083 0.30 13.90 284 260
2025: Q4 2.17 85.60 1,160 5.10 28.80 321 267
2026: Q1 0.87 5.60 1,091 4.80 12.30 289 251
2026: Q2 1.35 -10.00 1,159 9.60 17.90 201 161
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 2,398 587 463 3.13 687 2,270 4,281
2017 2,752 606 726 4.91 875 2,844 5,257
2018 3,333 883 826 5.54 1,142 3,845 6,959
2019 3,543 985 1,002 6.72 1,051 4,613 7,316
2020 3,239 393 656 4.43 1,080 4,694 7,585
2021 4,526 -123 762 5.05 545 10,740 15,217
2022 4,584 -4,179 -4,404 -28.05 392 6,599 12,252
2023 4,504 -1,069 -1,161 -7.35 478 5,745 10,111
2024 4,372 -833 -1,223 -7.69 837 2,373 6,303
2025 4,338 864 850 5.45 1,079 2,723 6,644

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

About the Company

Illumina, Inc. bietet sequenzierungs- und array-basierte Lösungen für die genetische und genomische Analyse in Nord- und Südamerika, Europa, Greater China, dem asiatisch-pazifischen Raum, dem Nahen Osten und Afrika an.

Employees8,600
HeadquartersSan Diego, CA
Address5200 Illumina Way, 92122 San Diego, United States
Phone858 202 4500
Websiteillumina.com
IPO Date28. Jul 2000
ISINUS4523271090
Stock Split1028:1000 on 06/25/2024

Management

Management
Name Title Birth Year
Ankur Dhingra CPA Chief Financial Officer 1976
Kevin Carl Pegels Chief of Global Operations 1968
Steven Barnard Ph.D. Chief Technology Officer 1961
Stephanie Campos President
Scott Ericksen VP & Chief Accounting Officer 1973
Mark Field Chief Information Officer 1971
Conor Noel McNamara C.F.A. VP of Investor Relations
Scott Davies Chief Legal Officer & Secretary 1970
Jakob Wedel Chief Strategy & Corporate Development Officer 1972
Patricia Leckman Senior VP & Chief People Officer 1964

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?